Based on the speaker's experience with blinatumomab plus ponatinib in Ph+ ALL, when does she suggest TKI discontinuation may be feasible?
Once the patient reaches MRD negativity by flow cytometry at the end of induction, regardless of line of therapy
When the patient has sustained a complete molecular response for two years, with a careful risk-benefit discussion for those treated in the third line or later
Only after allogeneic stem cell transplant in CR1, once the patient has completed at least five years of TKI maintenance